Alkem Laboratories has reported a solid year-on-year performance for the September quarter, reflecting consistent demand across key therapeutic areas and a healthier operating profile.
For Q2, the company’s net profit came in at ₹765 crore, marking an 11.1% rise compared to ₹688.6 crore in the same period last year. Revenue for the quarter touched ₹4,001 crore, up 17.2% from ₹3,414.6 crore YoY, showing stable traction in both domestic formulations and international markets.
Operating performance also improved. EBITDA increased 22% to ₹921 crore against ₹753 crore a year ago, indicating better cost management and operating leverage. The EBITDA margin stood at 23%, slightly higher than last year’s 22%, reflecting a more efficient quarter.
Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
